Among the above mechanisms, high-level MET amplification (11–26%), HGF secretion and MET overexpression were frequently detected in EGFR-TKIs resistant NSCLC, especially acquired third generation EGFR-TKIs resistance [10], which indicate that the (MET)/hepatocyte growth factor (HGF) pathway becomes an important resistant mechanism especially in third-generation EGFR-TKIs resistant NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.